<- Go Home

Nexalin Technology, Inc.

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer’s disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

Market Cap

$52.8M

Volume

948.9K

Cash and Equivalents

$81.4K

EBITDA

-$6.5M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$127.8K

Profit Margin

78.82%

52 Week High

$4.36

52 Week Low

$0.25

Dividend

N/A

Price / Book Value

10.65

Price / Earnings

-6.14

Price / Tangible Book Value

11.21

Enterprise Value

$48.2M

Enterprise Value / EBITDA

-7.43

Operating Income

-$6.5M

Return on Equity

135.57%

Return on Assets

-83.89

Cash and Short Term Investments

$4.6M

Debt

N/A

Equity

$5.0M

Revenue

$162.1K

Unlevered FCF

-$1.8M

Sector

Health Care Equipment and Supplies

Category

N/A

Company Stock Pitches